General Notes
This product (Catalog No. DPABH-03926) is a rabbit-derived polyclonal antibody raised against human CCNI. This antibody exhibits cross-reactivity with CCNI from mouse. It has been affinity purified by Protein A. CCNI, also known as Cyclin I, is a protein-coding gene located on the long arm of human chromosome 4 at position 4q21.1, encoding a member of the highly conserved but atypical cyclin family that regulates cyclin-dependent kinases (CDKs) critical for cell cycle progression and cellular survival. The gene spans 8 exons and produces a transcript expressed constitutively throughout the cell cycle, distinguishing it from canonical cyclins with periodic abundance; its protein product exhibits the highest sequence similarity to cyclin G among family members. Discovered through isolation from human brain tissue in 1995, CCNI features a single cyclin box domain (CBD) essential for CDK binding, classifying it as an atypical cyclin due to its unique amino acid context and preference for non-cell-cycle CDKs. Functionally, CCNI acts as a regulatory subunit that activates atypical CDKs, particularly CDK5, forming a CCNI-CDK5 complex that promotes anti-apoptotic signaling via the MEK/ERK pathway, upregulating proteins like Bcl-2 and Bcl-XL to protect postmitotic cells from apoptosis. This complex is notably involved in podocyte survival in kidney glomeruli, supporting glomerular integrity. Additionally, CCNI can activate CDK6 to drive E2F-mediated transcription, enhancing proliferation in cancer cells, and associates with CDK5 to confer cisplatin resistance in cervical cancer. The protein localizes to the cytoplasm, nucleus, Golgi apparatus, and nuclear membrane, participating in cyclin-dependent protein kinase holoenzyme complexes. CCNI exhibits ubiquitous expression across human tissues, with the highest levels in the thyroid (RPKM 185.4) and ovary (RPKM 178.6), and is detectable in fetal tissues such as adrenal, heart, kidney, and lung from 10 to 20 weeks gestation. In disease contexts, its overexpression correlates with poor prognosis in lung adenocarcinoma, where it drives proliferation in lung cancer cell lines, and its mRNA in saliva has been proposed as a potential biomarker for lung cancer detection. While no direct monogenic disorders are firmly linked to CCNI variants, its roles in cancer progression and drug resistance highlight its therapeutic relevance.
DPABH-03926 is suitable for use in WB 1 (1000-3000) application.
DPABH-03926 is supplied as a liquid formulation in Phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
COA
Publication 
Loading ......
